Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
- Resource Type
- Source
- Annals of the Rheumatic Diseases, Vol. 80, No 1 (2021) pp. 71-87
- Subject
Rheumatoid/drug therapy/immunology Piperidines/therapeutic use Advisory Committees Antirheumatic Agents/therapeutic use Psoriasis/drug therapy/immunology Azetidines/therapeutic use Psoriatic/drug therapy/immunology Cytokines/immunology Pyrazoles/therapeutic use Drug Therapy Rheumatology Heterocyclic Compounds Humans Purines/therapeutic use Pyridines/therapeutic use ddc:616 Adamantane/analogs & derivatives/therapeutic use Arthritis Janus Kinase Inhibitors/therapeutic use Inflammatory Bowel Diseases/drug therapy/immunology Pyrimidines/therapeutic use Sulfonamides/therapeutic use Europe Combination 3-Ring/therapeutic use Niacinamide/analogs & derivatives/therapeutic use Spondylarthropathies/drug therapy/immunology Ankylosing/drug therapy/immunology Triazoles/therapeutic use Spondylitis - Language
- English
- ISSN
- 0003-4967